The DOI matches its Crossref record; 119 of the 119 references it cites were found in a registry or an index.
Liposomal Amphotericin B (AmBisome®): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions
Open accessAbstract
Liposomal amphotericin B (AmBisome(®); LAmB) is a unique lipid formulation of amphotericin B. LAmB is a standard of care for a wide range of medically important opportunistic fungal pathogens. LAmB has a significantly improved toxicity profile compared with conventional amphotericin B deoxycholate (DAmB). Despite nearly 20 years of clinical use, the pharmacokinetics and pharmacodynamics of this agent, which differ considerably from DAmB, remain relatively poorly understood and underutilized in the clinical setting. The molecular pharmacology, preclinical and clinical pharmacokinetics, and clinical experience with LAmB for the most commonly encountered fungal pathogens are reviewed. In vitro, experimental animal models and human clinical trial data are summarized, and novel routes of administration and dosing schedules are discussed. LAmB is a formulation that results in reduced toxicity as compared with DAmB while retaining the antifungal effect of the active agent. Its long terminal half-life and retention in tissues suggest that single or intermittent dosing regimens are feasible, and these should be actively investigated in both preclinical models and in clinical trials. Significant gaps remain in knowledge of pharmacokinetics and pharmacodynamics in special populations such as neonates and children, pregnant women and obese patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Liposome bilayer-coated amphotericin B (LAmB) has been developed to reduce toxicity while retaining antifungal activity, mitigating the dosage limitation of conventional amphotericin B deoxycholate (DAmB)9.”
From Treatment strategies for cryptococcal infection: challenges, advances and future outlook (2021) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diffusion of univalent ions across the lamellae of swollen phospholipids
Bangham, A. D., Standish, M. M., & Watkins, J. C. (1965) · Journal of Molecular Biology · doi:10.1016/s0022-2836(65)80093-6 · Cited by 4,664
Szer, J. (1999) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.1999.tb127745.x · Cited by 3,373
Walsh, T. J., Anaissie, E. J., Denning, D. W., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Segal, B. H., Steinbach, W. J., Stevens, D. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/525258 · Cited by 2,705
Perfect, J. R., Dismukes, W. E., Dromer, F., Goldman, D. L., Graybill, J. R., Hamill, R. J., Harrison, T. S., Larsen, R. A., Lortholary, O., Nguyen, M.-H., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/649858 · Cited by 2,660
Liposomal Amphotericin B for Empirical Therapy in Patients with Persistent Fever and Neutropenia
Walsh, T. J., Finberg, R. W., Arndt, C., Hiemenz, J., Schwartz, C., Bodensteiner, D., Pappas, P., Seibel, N., Greenberg, R. N., Dummer, S., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903113401004 · Cited by 1,205
Papahadjopoulos, D., Jacobson, K., Nir, S., & Isac, I. (1973) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(73)90314-3 · Cited by 998
Walsh, T. J., Pappas, P., Winston, D. J., Lazarus, H. M., Petersen, F., Raffalli, J., Yanovich, S., Stiff, P., Greenberg, R., Donowitz, G., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejm200201243460403 · Cited by 979
Walsh, T. J., Teppler, H., Donowitz, G. R., Maertens, J. A., Baden, L. R., Dmoszyńska, A., Cornely, O. A., Bourque, M. R., Lupinacci, R. J., Sable, C. A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040446 · Cited by 907
Amphotericin B formulations: a comparative review of efficacy and toxicity
Hamill, R. J. (2013) · Drugs · doi:10.1007/s40265-013-0069-4 · Cited by 807
Cornely, O. A., Maertens, J. A., Bresnik, M., Ebrahimi, R., Ullmann, A. J., Bouza, E., Heußel, C. P., Lortholary, O., Rieger, C. T., Boehme, A., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/514341 · Cited by 744
Research works printed but not linked: 1
- Joint Formulary Committee. British National Formulary. 70th ed. London: BMJ Group and Pharmaceutical Press;2015.
Cited by
Sorted by citations
Aspergillus fumigatus and Aspergillosis in 2019
Latgé, J.-P., & Chamilos, G. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00140-18 · Cited by 1,400
Mehta, M., Bui, T. A., Yang, X., Aksoy, Y. A., Goldys, E. M., & Deng, W. (2023) · ACS Materials Au · doi:10.1021/acsmaterialsau.3c00032 · Cited by 776
Nanopharmaceuticals and Nanomedicines Currently on the Market: Challenges and Opportunities
Farjadian, F., Ghasemi, A., Gohari, O., Roointan, A., Karimi, M., & Hamblin, M. R. (2018) · Nanomedicine · doi:10.2217/nnm-2018-0120 · Cited by 703
Recent advancements in liposome technology
Filipczak, N., Pan, J., Yalamarty, S. S. K., & Torchilin, V. P. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.022 · Cited by 611
Multifunctional nanoparticle-mediated combining therapy for human diseases
Li, X., Peng, X., Zoulikha, M., Boafo, G. F., Magar, K. T., Ju, Y., & He, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01668-1 · Cited by 573
Biocompatibility of nanomaterials and their immunological properties
Kyriakides, T. R., Raj, A., Tseng, T. H., Xiao, H., Nguyen, R. Y., Mohammed, F. S., Halder, S. S., Xu, M., Wu, M. J., Bao, S., et al. (2021) · Biomedical Materials · doi:10.1088/1748-605x/abe5fa · Cited by 421
Cavassin, F. B., Baú-Carneiro, J. L., Boas, R. R. V., & Queiroz‐Telles, F. (2021) · Infectious Diseases and Therapy · doi:10.1007/s40121-020-00382-7 · Cited by 403
Treatment strategies for cryptococcal infection: challenges, advances and future outlook
Iyer, K. R., Revie, N. M., Fu, C., Robbins, N., & Cowen, L. E. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00511-0 · Cited by 363
Leishmaniasis in humans: drug or vaccine therapy?
Ghorbani, M., & Farhoudi, R. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s146521 · Cited by 356
Amphotericin B and Other Polyenes—Discovery, Clinical Use, Mode of Action and Drug Resistance
Carolus, H., Pierson, S., Lagrou, K., & Dijck, P. V. (2020) · Journal of Fungi · doi:10.3390/jof6040321 · Cited by 387
Candida parapsilosis: from genes to the bedside
Tóth, R., Nosek, J., Mora-Montes, H. M., Gabaldon, T., Bliss, J. M., Nosanchuk, J. D., Turner, S. A., Butler, G., Vágvölgyi, C., & Gácser, A. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00111-18 · Cited by 327
Desai, N., Rana, D., Patel, M., Bajwa, N., Prasad, R., & Vora, L. K. (2025) · Small · doi:10.1002/smll.202502315 · Cited by 341
Why nanoparticles prefer liver macrophage cell uptake in vivo
Ngo, W., Ahmed, S., Blackadar, C., Bussin, B., Ji, Q. C., Mladjenovic, S. M., Sepahi, Z., & Chan, W. C. W. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114238 · Cited by 266
Phytochemical delivery through nanocarriers: a review
Ahmad, R., Srivastava, S., Ghosh, S., & Khare, S. K. (2020) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2020.111389 · Cited by 216
Nanocarriers for the Delivery of Medical, Veterinary, and Agricultural Active Ingredients
Chariou, P. L., Ortega-Rivera, O. A., & Steinmetz, N. F. (2020) · ACS Nano · doi:10.1021/acsnano.0c00173 · Cited by 215
Solubilization techniques used for poorly water-soluble drugs
Xie, B., Liu, Y., Li, X., Yang, P., & He, W. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.08.027 · Cited by 241
Cryptococcus neoformans, a global threat to human health
Zhao, Y., Ye, L., Zhao, F., Zhang, L., Lu, Z., Chu, T., Wang, S., Liu, Z., Sun, Y., Chen, M., et al. (2023) · Infectious Diseases of Poverty · doi:10.1186/s40249-023-01073-4 · Cited by 217
Safe nanomaterials: from their use, application, and disposal to regulations
Chávez-Hernández, J. A., Velarde‐Salcedo, A. J., Navarro‐Tovar, G., & González, C. (2024) · Nanoscale Advances · doi:10.1039/d3na01097j · Cited by 212
Targeting of Hepatic Macrophages by Therapeutic Nanoparticles
Colino, C. I., Lanao, J. M., & Millán, C. G. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00218 · Cited by 189
Liposome-based delivery of biological drugs
Magar, K. T., Boafo, G. F., Li, X., Chen, Z., & He, W. (2021) · Chinese Chemical Letters · doi:10.1016/j.cclet.2021.08.020 · Cited by 189
Walker, L. A., Sood, P., Lenardon, M. D., Milne, G., Olson, J. A., Jensen, G. M., Wolf, J. M., Casadevall, A., Adler‐Moore, J., & Gow, N. A. R. (2018) · mBio · doi:10.1128/mbio.02383-17 · Cited by 170
Man, F., Gawne, P. J., & de Rosales, R. T. M. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.05.012 · Cited by 163
Approved Nanomedicine against Diseases
Jia, Y., Jiang, Y., He, Y., Zhang, W., Zou, J., Magar, K. T., Boucetta, H., Teng, C., & He, W. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030774 · Cited by 178
Emerging Antifungal Targets and Strategies
Ivanov, M., Ćirić, A., & Stojković, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052756 · Cited by 160
Hoenigl, M., Arastehfar, A. A., Arendrup, M. C., Brüggemann, R. J. M., Carvalho, A., Chiller, T. M., Chen, W., Egger, M., Feys, S., Gangneux, J., et al. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00074-23 · Cited by 165
Jenks, J. D., & Hoenigl, M. (2018) · Journal of Fungi · doi:10.3390/jof4030098 · Cited by 146
The Impact of Nanoparticles on the Immune System: A Gray Zone of Nanomedicine
Ray, P., Haideri, N., Haque, I., Mohammed, O. F., Chakraborty, S., Banerjee, S., Quadir, M., Brinker, A. E., & Banerjee, S. K. (2021) · Journal of Immunological Sciences · doi:10.29245/2578-3009/2021/1.1206 · Cited by 146
Clinical Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Liposomal Amphotericin B
Groll, A. H., Rijnders, B. J. A., Walsh, T. J., Adler‐Moore, J., Lewis, R. E., & Brüggemann, R. J. M. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz076 · Cited by 140
Emerging New Targets for the Treatment of Resistant Fungal Infections
Liu, N., Tu, J., Dong, G., Wang, Y., & Sheng, C. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01413 · Cited by 129
Microfluidic Manufacture of Lipid-Based Nanomedicines
Osouli-Bostanabad, K., Puliga, S., Serrano, D. R., Bucchi, A., Halbert, G., & Lalatsa, A. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091940 · Cited by 137
Understanding nanoparticle-liver interactions in nanomedicine
He, Y., Wang, Y., Wang, L., Jiang, W., & Wilhelm, S. (2024) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2024.2375400 · Cited by 145
Tugume, L., Ssebambulidde, K., Kasibante, J., Ellis, J. P., Wake, R. M., Gakuru, J., Lawrence, D. S., Abassi, M., Rajasingham, R., Meya, D. B., et al. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00472-z · Cited by 140
Recent Progress of Nanocarrier-Based Therapy for Solid Malignancies
Wei, Q.-Y., Xu, Y., & Lau, A. T. Y. (2020) · Cancers · doi:10.3390/cancers12102783 · Cited by 121
Wang, Z., Wang, X., Xu, W., Li, Y., Lai, R., Qiu, X., Chen, X., Chen, Z., Mi, B., Wu, M., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15112623 · Cited by 128
Antifungals and Drug Resistance
Hossain, C. M., Ryan, L. K., Gera, M., Choudhuri, S., Lyle, N., Ali, K. A., & Diamond, G. (2022) · Encyclopedia · doi:10.3390/encyclopedia2040118 · Cited by 135
Stott, K. E., & Hope, W. W. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx029 · Cited by 115
Self-citationRegulating nanomedicines: challenges, opportunities, and the path forward
Mangla, B., Kumar, P., Javed, S., Pathan, T., Ahsan, W., & Aggarwal, G. (2025) · Nanomedicine · doi:10.1080/17435889.2025.2533107 · Cited by 126
Mechanisms and Barriers in Nanomedicine: Progress in the Field and Future Directions
Anchordoquy, T. J., Artzi, N., Balyasnikova, I. V., Barenholz, Y., La-Beck, N. M., Brenner, J. S., Chan, W. C. W., Decuzzi, P., Exner, A. A., Gabizón, A., et al. (2024) · ACS Nano · doi:10.1021/acsnano.4c00182 · Cited by 116
Mucormycosis in Children: Review and Recommendations for Management
Francis, J. R., Villanueva, P., Bryant, P. A., & Blyth, C. C. (2017) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/pix107 · Cited by 109
Liposome bilayer stability: emphasis on cholesterol and its alternatives
Nsairat, H., Ibrahim, A. A., Jaber, A. M., Abdelghany, S. M., Atwan, R., Shalan, N. M., Abdelnabi, H., Odeh, F., El‐Tanani, M., & Alshaer, W. (2023) · Journal of Liposome Research · doi:10.1080/08982104.2023.2226216 · Cited by 118
Nanotools for Sepsis Diagnosis and Treatment
Papafilippou, L., Claxton, A., Dark, P., Kostarelos, K., & Hadjidemetriou, M. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202001378 · Cited by 118
Small-molecule ion channels increase host defences in cystic fibrosis airway epithelia
Muraglia, K. A., Chorghade, R. S., Kim, B. R., Tang, X. X., Shah, V. S., Grillo, A. S., Daniels, P. N., Cioffi, A. G., Karp, P. H., Zhu, L., et al. (2019) · Nature · doi:10.1038/s41586-019-1018-5 · Cited by 109
John, J., Loo, A. S., Mazur, S., & Walsh, T. J. (2019) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2019.1671971 · Cited by 108
Altamura, F., Rajesh, R., Catta‐Preta, C. M. C., Moretti, N. S., & Cestari, I. D. S. (2020) · Drug Development Research · doi:10.1002/ddr.21664 · Cited by 106
Nano-based drug delivery system for therapeutics: a comprehensive review
Prakash, S. (2023) · Biomedical Physics & Engineering Express · doi:10.1088/2057-1976/acedb2 · Cited by 113
Approved and marketed nanoparticles for disease targeting and applications in COVID-19
Abdellatif, A. A. H., & Alsowinea, A. F. (2021) · Nanotechnology Reviews · doi:10.1515/ntrev-2021-0115 · Cited by 105
The impact of obesity on immune response to infection: Plausible mechanisms and outcomes
Muscogiuri, G., Pugliese, G., Laudisio, D., Castellucci, B., Barrea, L., Savastano, S., & Colao, A. (2021) · Obesity Reviews · doi:10.1111/obr.13216 · Cited by 94
Lipid-Based Nanotechnology: Liposome
Jiang, Y., Li, W., Wang, Z., & Lu, J. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics16010034 · Cited by 102
Amphotericin B: A drug of choice for Visceral Leishmaniasis
Kumari, S., Kumar, V., Tiwari, R. K., Ravidas, V., Pandey, K., & Kumar, A. (2022) · Acta Tropica · doi:10.1016/j.actatropica.2022.106661 · Cited by 95
Topical delivery of pharmaceutical and cosmetic macromolecules using microemulsion systems
Szumała, P., & Macierzanka, A. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.121488 · Cited by 93
Clinical Pharmacokinetics of Systemically Administered Antileishmanial Drugs
Kip, A. E., Schellens, J. H. M., Beijnen, J. H., & Dorlo, T. P. C. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0570-0 · Cited by 84
Adler‐Moore, J., Lewis, R. E., Brüggemann, R. J. M., Rijnders, B. J. A., Groll, A. H., & Walsh, T. J. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz064 · Cited by 85
Carbon Dots as Drug Delivery Vehicles for Antimicrobial Applications: A Minireview
Wang, Z., Wang, Z., & Wu, F. (2022) · ChemMedChem · doi:10.1002/cmdc.202200003 · Cited by 83
Biofilms and Chronic Wounds: Pathogenesis and Treatment Options
Shen, A., Taha, M. R., Ghannoum, M. A., & Tyring, S. K. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14217784 · Cited by 99
Efficacy and safety of amphotericin B lipid‐based formulations—A systematic review and meta‐analysis
Steimbach, L. M., Tonin, F. S., Virtuoso, S., Borba, H. H. L., Sanches, A. C. C., Wiens, A., Fernández-Llimós, F., & Pontarolo, R. (2016) · Mycoses · doi:10.1111/myc.12585 · Cited by 81
He, H., Yuan, D., Wu, Y., & Cao, Y. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11030110 · Cited by 80
Engineering Tumor-Targeting Nanoparticles as Vehicles for Precision Nanomedicine
Gonda, A., Zhao, N., Shah, J. V., Calvelli, H. R., Kantamneni, H., Francis, N. L., & Ganapathy, V. (2019) · Med One · doi:10.20900/mo.20190021 · Cited by 83
Antileishmanial Drug Discovery and Development: Time to Reset the Model?
Olías-Molero, A. I., de la Fuente, C., Cuquerella, M., Torrado, J. J., & Alunda, J. M. (2021) · Microorganisms · doi:10.3390/microorganisms9122500 · Cited by 83
Pharmaceutical liposomal delivery—specific considerations of innovation and challenges
Peng, T., Xu, W., Li, Q., Ding, Y., & Huang, Y. (2022) · Biomaterials Science · doi:10.1039/d2bm01252a · Cited by 82
Nanotechnology based solutions for anti-leishmanial impediments: a detailed insight
Jamshaid, H., Din, F. U., & Khan, G. M. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-00853-0 · Cited by 76
Liposomal amphotericin B in travelers with cutaneous and muco-cutaneous leishmaniasis: Not a panacea
Guéry, R., Henry, B., Martin‐Blondel, G., Rouzaud, C., Cordoliani, F., Harms, G., Gangneux, J., Foulet, F., Bourrat, E., Baccard, M., et al. (2017) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0006094 · Cited by 71
Amphotericin B-loaded nanoparticles for local treatment of cutaneous leishmaniasis
Ammar, A. A., Nasereddin, A., Ereqat, S., Dan‐Goor, M., Jaffe, C. L., Zussman, E., & Abdeen, Z. (2018) · Drug Delivery and Translational Research · doi:10.1007/s13346-018-00603-0 · Cited by 70
Multivesicular Vesicles: Preparation and Applications
Giuliano, C. B., Cvjetan, N., Ayache, J., & Walde, P. (2020) · ChemSystemsChem · doi:10.1002/syst.202000049 · Cited by 71
Cuddihy, G., Wasan, E. K., Di, Y., & Wasan, K. M. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11030099 · Cited by 69
Ionic Liquids in Drug Delivery
Pedro, S. N., Freire, C. S. R., Silvestre, A. J. D., & Freire, M. G. (2021) · Encyclopedia · doi:10.3390/encyclopedia1020027 · Cited by 68
Protein corona fingerprinting to differentiate sepsis from non-infectious systemic inflammation
Papafilippou, L., Claxton, A., Dark, P. M., Kostarelos, K., & Hadjidemetriou, M. (2020) · Nanoscale · doi:10.1039/d0nr02788j · Cited by 65
Nanoparticles for drug delivery in Parkinson’s disease
Baskin, J., Jeon, J. E., & Lewis, S. J. G. (2020) · Journal of Neurology · doi:10.1007/s00415-020-10291-x · Cited by 67
Prasanna, P., Kumar, P., Kumar, S., Rajana, V. K., Kant, V., Prasad, S. R., Mohan, U., Ravichandiran, V., & Mandal, D. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111920 · Cited by 67
Francesco, M. A. D. (2023) · Pathogens · doi:10.3390/pathogens12111305 · Cited by 69
Recent advances in amphotericin B delivery strategies for the treatment of leishmaniases
Lanza, J. S., Pomel, S., Loiseau, P. M., & Frézard, F. (2019) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2019.1659243 · Cited by 62
Transmembrane Ion Channels: From Natural to Artificial Systems
Yan, T., & Liu, J. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202416200 · Cited by 62
Dectin-1-Targeted Antifungal Liposomes Exhibit Enhanced Efficacy
Ambati, S., Ferraro, A. R., Kang, S., Lin, J., Lin, X., Momany, M., Lewis, Z., & Meagher, R. B. (2019) · mSphere · doi:10.1128/msphere.00025-19 · Cited by 63
Lysosomal nanotoxicity: Impact of nanomedicines on lysosomal function
Uzhytchak, M., Smolková, B., Lunová, M., Frtús, A., Jirsa, M., Dejneka, A., & Lunov, O. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114828 · Cited by 61
Advances in Biomaterials for the Prevention and Disruption of Candida Biofilms
Vera‐González, N., & Shukla, A. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.538602 · Cited by 61
Haro-Reyes, T., Díaz-Peralta, L., Galván‐Hernández, A., Rodríguez‐López, A., Rodríguez‐Fragoso, L., & Ortega‐Blake, I. (2022) · Membranes · doi:10.3390/membranes12070681 · Cited by 59
Immune Implications of Cholesterol-Containing Lipid Nanoparticles
Back, P. I., Yu, M., Modaresahmadi, S., Hajimirzaei, S., Zhang, Q., Islam, M. R., Schwendeman, A. A., & La-Beck, N. M. (2024) · ACS Nano · doi:10.1021/acsnano.4c06369 · Cited by 60
Emerging nanotechnologies for targeting antimicrobial resistance
Weldrick, P. J., Wang, A., Halbus, A. F., & Paunov, V. N. (2022) · Nanoscale · doi:10.1039/d1nr08157h · Cited by 55
Current and promising novel drug candidates against visceral leishmaniasis
Reguera, R. M., Pérez‐Pertejo, Y., Gutiérrez-Corbo, C., Domínguez-Asenjo, B., Ordóñez, C., García‐Estrada, C., Valladares, M. M., & Balaña‐Fouce, R. (2019) · Pure and Applied Chemistry · doi:10.1515/pac-2018-1102 · Cited by 56
Screening Marine Natural Products for New Drug Leads against Trypanosomatids and Malaria
Álvarez-Bardón, M., Pérez‐Pertejo, Y., Ordóñez, C., Sepúlveda‐Crespo, D., Carballeira, N. M., Tekwani, B. L., Murugesan, S., Valladares, M. M., García‐Estrada, C., Reguera, R. M., et al. (2020) · Marine Drugs · doi:10.3390/md18040187 · Cited by 59
Nano-formulations in disease therapy: designs, advances, challenges, and future directions
Shi, Y., Li, X., Li, Z., Sun, J., Gao, T., Wei, G., & Guo, Q. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03442-7 · Cited by 58
Li, J., Tan, T., Zhao, L., Liu, M., You, Y., Zeng, Y., Chen, D., Xie, T., Zhang, L., Fu, C., et al. (2020) · ACS Applied Bio Materials · doi:10.1021/acsabm.0c00705 · Cited by 51
Lipid and fatty acid metabolism in trypanosomatids
de Aquino, G. P., Gomes, M. A. M., Salinas, R. K., & Laranjeira‐Silva, M. F. (2021) · Microbial Cell · doi:10.15698/mic2021.11.764 · Cited by 50
Shirzadi, M. R. (2019) · Research and Reports in Tropical Medicine · doi:10.2147/rrtm.s200218 · Cited by 49
Vera‐González, N., Bailey‐Hytholt, C. M., Langlois, L., Ribeiro, F. D. C., Santos, E. L. D. S., Junqueira, J. C., & Shukla, A. (2020) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.36984 · Cited by 49
Antifungal therapy: Novel drug delivery strategies driven by new targets
Wu, S., Song, R., Liu, T., & Li, C. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114967 · Cited by 52
Nanotechnology in the Diagnosis and Treatment of Antibiotic-Resistant Infections
Ιωάννου, Π., Baliou, S., & Samonis, G. (2024) · Antibiotics · doi:10.3390/antibiotics13020121 · Cited by 50
Advances in functional lipid nanoparticles: from drug delivery platforms to clinical applications
Dhayalan, M., Wang, W., Riyaz, S. U. M., Dinesh, R. A., Shanmugam, J., Irudayaraj, S. S., Stalin, A., Giri, J. P., Mallik, S., & Hu, R. (2024) · 3 Biotech · doi:10.1007/s13205-023-03901-8 · Cited by 50
Prevention of paclitaxel-induced neuropathy by formulation approach
Zang, X., Lee, J. B., Deshpande, K., Garbuzenko, O. B., Minko, T., & Kagan, L. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.04.013 · Cited by 47
Recent drug development and treatments for fungal infections
Roy, M., Karhana, S., Shamsuzzaman, M., & Khan, M. A. (2023) · Brazilian Journal of Microbiology · doi:10.1007/s42770-023-00999-z · Cited by 47
Molecular Mechanisms of Drug Resistance in Leishmania spp.
Moncada-Díaz, M. J., Rodríguez-Almonacid, C. C., Quiceno, E., Khuong, F. T. H., Muskus, C., & Karamysheva, Z. N. (2024) · Pathogens · doi:10.3390/pathogens13100835 · Cited by 47
Dectin-2-Targeted Antifungal Liposomes Exhibit Enhanced Efficacy
Ambati, S., Ellis, E. C., Lin, J., Lin, X., Lewis, Z., & Meagher, R. B. (2019) · mSphere · doi:10.1128/msphere.00715-19 · Cited by 51
Pre-Existing Liver Disease and Toxicity of Antifungals
Spernovasilis, N. A., & Kofteridis, D. P. (2018) · Journal of Fungi · doi:10.3390/jof4040133 · Cited by 45
Zakaria, A., Osman, M., Dabboussi, F., Rafei, R., Mallat, H., Papon, N., Bouchara, J., & Hamzé, M. (2019) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2019.08.007 · Cited by 46
Jafari, M., Abolmaali, S. S., Tamaddon, A. M., Zomorodian, K., & Sarkari, B. (2021) · Nanomedicine · doi:10.2217/nnm-2020-0482 · Cited by 44
Polyphenols against infectious diseases: Controlled release nano-formulations
Murthy, N. T. V., Agrahari, V., & Chauhan, H. (2021) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2021.02.003 · Cited by 43
Advancing Medicine with Lipid-Based Nanosystems—The Successful Case of Liposomes
Luiz, H., Pinho, J. O., & Gaspar, M. M. (2023) · Biomedicines · doi:10.3390/biomedicines11020435 · Cited by 50
Overview of antifungal dosing in invasive candidiasis
Pea, F., & Lewis, R. E. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx447 · Cited by 43
Matsuura-Sawada, Y., Maeki, M., Uno, S., Wada, K., & Tokeshi, M. (2023) · Biomaterials Science · doi:10.1039/d2bm01703b · Cited by 46
Targeting and synergistic action of an antifungal peptide in an antibiotic drug-delivery system
Park, S., Kim, Y., Lee, J., Kim, N.-H., Kim, E.-J., Heo, H., Lee, M. Y., Lee, J. R., & Jang, M.-K. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.04.023 · Cited by 41
Review of methods and antimicrobial agents for susceptibility testing against Pythium insidiosum
Yolanda, H., & Krajaejun, T. (2020) · Heliyon · doi:10.1016/j.heliyon.2020.e03737 · Cited by 41
Metadata
- Authors
- Stone, N. R. H., Bicanic, T., Salim, R., & Hope, W.
- Affiliations
- St George's, University of London (GB)
- Royal Liverpool University Hospital (GB)
- University of Liverpool (GB)
- Corresponding author
- Stone, Neil R. H.
- Venue
- Drugs
- Published
- 2016-01-27
- Volume
- 76
- Issue
- 4
- Pages
- 485-500
- ISSN
- 0012-6667 (ISSN-L)
- 1179-1950
- PMC
- PMC4856207
- OpenAlex
- W2298912458
- Cited by
- 537
- References
- 119
- Citations by year
- 2026: 52 · 2025: 81 · 2024: 73 · 2023: 61 · 2022: 73 · 2021: 60 · 2020: 55 · 2019: 40 · 2018: 16 · 2017: 23 · 2016: 1
- FWCI
- 4.10
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Drugs (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Wellcome Trust Strategic Award (Medical Mycology and Fungal Immunology) (RG12848-10)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Keywords
- liposomal amphotericin B, amphotericin B deoxycholate, pharmacokinetics, pharmacodynamics, antifungal agents, opportunistic fungal infection, drug toxicity, dosing regimen, intermittent dosing, neonates, pregnancy, obesity, molecular pharmacology
- MeSH terms
- Amphotericin B, Animals, Chemistry, Pharmaceutical, Clinical Trials as Topic, Deoxycholic Acid, Drug Combinations, Half-Life, Humans, Tissue Distribution
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
